Francesca N Delling1, Xinjun Li2, Shuo Li2, Qiong Yang2, Vanessa Xanthakis2, Andreas Martinsson2, Pontus Andell2, Birgitta T Lehman2, Ewa W Osypiuk2, Plamen Stantchev2, Bengt Zöller2, Emelia J Benjamin2, Kristina Sundquist2, Ramachandran S Vasan2, J Gustav Smith2. 1. From the Boston University's and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (F.N.D., B.T.L., E.W.O., P.S., E.J.B., R.S.V.); Cardiovascular Division, Department of Medicine, University of California San Francisco (F.N.D.); Center for Primary Health Care Research, Lund University, Malmö, Sweden (X.L., B.Z., K.S.); Department of Biostatistics (S.L., Q.Y., V.X.), Department of Epidemiology (V.X., E.J.B., R.S.V.), and Cardiology and Preventive Medicine Sections, Department of Medicine (E.J.B., R.S.V.), Boston University School of Medicine, MA; Department of Cardiology, Clinical Sciences, Lund University, Sweden (A.M., P.A., J.G.S.); and Skåne University Hospital, Lund, Sweden (A.M., P.A., J.G.S.). Francesca.Delling@ucsf.edu. 2. From the Boston University's and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (F.N.D., B.T.L., E.W.O., P.S., E.J.B., R.S.V.); Cardiovascular Division, Department of Medicine, University of California San Francisco (F.N.D.); Center for Primary Health Care Research, Lund University, Malmö, Sweden (X.L., B.Z., K.S.); Department of Biostatistics (S.L., Q.Y., V.X.), Department of Epidemiology (V.X., E.J.B., R.S.V.), and Cardiology and Preventive Medicine Sections, Department of Medicine (E.J.B., R.S.V.), Boston University School of Medicine, MA; Department of Cardiology, Clinical Sciences, Lund University, Sweden (A.M., P.A., J.G.S.); and Skåne University Hospital, Lund, Sweden (A.M., P.A., J.G.S.).
Abstract
BACKGROUND: Familial aggregation has been described for primary mitral regurgitation (MR) caused by mitral valve prolapse. We hypothesized that heritability of MR exists across different MR subtypes including nonprimary MR. METHODS AND RESULTS: Study participants were FHS (Framingham Heart Study) Generation 3 (Gen 3) and Gen 2 cohort participants and all adult Swedish siblings born after 1932 identified in 1997 and followed through 2010. MR was defined as ≥ mild regurgitation on color Doppler in FHS and from International Classification of Diseases codes in Sweden. We estimated the association of sibling MR with MR in Gen 2/Gen 3/Swedish siblings. We also estimated heritability of MR in 539 FHS pedigrees (7580 individuals). Among 5132 FHS Gen 2/Gen 3 participants with sibling information, 1062 had MR. Of siblings with sibling MR, 28% (500/1797) had MR compared with 17% (562/3335) without sibling MR (multivariable-adjusted odds ratio, 1.20; 95% confidence interval [CI], 1.01-1.43; P=0.04). When we combined parental and sibling data in FHS pedigrees, heritability of MR was estimated at 0.15 (95% CI, 0.07-0.23), 0.12 (95% CI, 0.04-0.20) excluding mitral valve prolapse, and 0.44 (95% CI, 0.15-0.73) for ≥ moderate MR only (all P<0.05). In Sweden, sibling MR was associated with a hazard ratio of 3.57 (95% CI, 2.21-5.76; P<0.001) for development of MR. CONCLUSIONS: Familial clustering of MR exists in the community, supporting a genetic susceptibility common to primary and nonprimary MR. Further studies are needed to elucidate the common regulatory pathways that may lead to MR irrespective of its cause.
BACKGROUND:Familial aggregation has been described for primary mitral regurgitation (MR) caused by mitral valve prolapse. We hypothesized that heritability of MR exists across different MR subtypes including nonprimary MR. METHODS AND RESULTS: Study participants were FHS (Framingham Heart Study) Generation 3 (Gen 3) and Gen 2 cohort participants and all adult Swedish siblings born after 1932 identified in 1997 and followed through 2010. MR was defined as ≥ mild regurgitation on color Doppler in FHS and from International Classification of Diseases codes in Sweden. We estimated the association of sibling MR with MR in Gen 2/Gen 3/Swedish siblings. We also estimated heritability of MR in 539 FHS pedigrees (7580 individuals). Among 5132 FHS Gen 2/Gen 3 participants with sibling information, 1062 had MR. Of siblings with sibling MR, 28% (500/1797) had MR compared with 17% (562/3335) without sibling MR (multivariable-adjusted odds ratio, 1.20; 95% confidence interval [CI], 1.01-1.43; P=0.04). When we combined parental and sibling data in FHS pedigrees, heritability of MR was estimated at 0.15 (95% CI, 0.07-0.23), 0.12 (95% CI, 0.04-0.20) excluding mitral valve prolapse, and 0.44 (95% CI, 0.15-0.73) for ≥ moderate MR only (all P<0.05). In Sweden, sibling MR was associated with a hazard ratio of 3.57 (95% CI, 2.21-5.76; P<0.001) for development of MR. CONCLUSIONS: Familial clustering of MR exists in the community, supporting a genetic susceptibility common to primary and nonprimary MR. Further studies are needed to elucidate the common regulatory pathways that may lead to MR irrespective of its cause.
Authors: Milos Pjanic; Clint L Miller; Robert Wirka; Juyong B Kim; Daniel M DiRenzo; Thomas Quertermous Journal: Curr Cardiol Rep Date: 2016-10 Impact factor: 2.931
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Miguel Chaput; Mark D Handschumacher; Francois Tournoux; Lanqi Hua; J Luis Guerrero; Gus J Vlahakes; Robert A Levine Journal: Circulation Date: 2008-08-04 Impact factor: 29.690
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Pontus Andell; Xinjun Li; Andreas Martinsson; Charlotte Andersson; Martin Stagmo; Bengt Zöller; Kristina Sundquist; J Gustav Smith Journal: Heart Date: 2017-04-21 Impact factor: 5.994
Authors: Yasmine L Hiemstra; Aniek L van Wijngaarden; Mathilde W Bos; Martin J Schalij; Robert Jm Klautz; Jeroen J Bax; Victoria Delgado; Daniela Qcm Barge-Schaapveld; Nina Ajmone Marsan Journal: Eur J Prev Cardiol Date: 2019-09-02 Impact factor: 7.804
Authors: Yasmine L Hiemstra; Anton Tomsic; Paola Gripari; Aniek L van Wijngaarden; Stéphanie L van der Pas; Meindert Palmen; Robert J M Klautz; Mauro Pepi; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan Journal: Interact Cardiovasc Thorac Surg Date: 2021-04-19